TCL Archive PD-1 Checkpoint Inhibitor Opdivo First to Demonstrate Survival Benefit in Phase III November 28, 2014
TCL Archive NCI Staff Discusses New Guidelines for Core Grant Reviews, Comprehensiveness July 24, 1992